European Journal of Surgical Oncology
Volume 35, Issue 10 , Pages 1030-1036 , October 2009

Prognostic factors in localized extremity osteosarcoma: A systematic review

  • J.A.M. Bramer

      Affiliations

    • Department of Orthopedic Surgery (G4 221), Academic Medical Center, Meibergdreef 9, P.O. Box 22660, 1100 DD Amsterdam, The Netherlands
    • Corresponding Author InformationCorresponding author. Tel.: +31 20 4723023; fax: +31 20 5669117.
    • ,
  • J.H. van Linge

      Affiliations

    • Department of Orthopedic Surgery, Erasmus Medical Centre, Dr Molewaterplein 50-60, 3015 GE Rotterdam, The Netherlands
    • ,
  • R.J. Grimer

      Affiliations

    • Oncology Service, Royal Orthopaedic Hospital, Bristol Road South, Northfield, Birmingham B31 2AP, United Kingdom
    • ,
  • R.J.P.M. Scholten

      Affiliations

    • Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Academic Medical Center, Meibergdreef 9, P.O. Box 22660, 1100 DD Amsterdam, The Netherlands

,Accepted 20 January 2009.

References 

  1. Davis AM, Bell RS, Goodwin PJ. Prognostic factors in osteosarcoma: a critical review. Journal of Clinical Oncology. 1994;12(2):423–431
  2. Weeden S, Grimer RJ, Cannon SR, Taminiau AH, Uscinska BM. The effect of local recurrence on survival in resected osteosarcoma. European Journal of Cancer. 2001;37(1):39–46
  3. Wilkins RM, Cullen JW, Camozzi AB, Jamroz BA, Odom L. Improved survival in primary nonmetastatic pediatric osteosarcoma of the extremity. Clinical Orthopaedics & Related Research. 2005;438:128–136Ref type: electronic citation
  4. Souhami RL, Craft AW, Van der Eijken JW, et al. Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European osteosarcoma intergroup. Lancet. 1997;350(9082):911–917
  5. Bacci G, Longhi A, Versari M, Mercuri M, Briccoli A, Picci P. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer. 2006;106(5):1154–1161
  6. Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. Journal of Clinical Oncology. 2002;20(3):776–790
  7. Link MP, Goorin AM, Horowitz M, et al. Adjuvant chemotherapy of high-grade osteosarcoma of the extremity: updated results of the multi-institutional osteosarcoma study. Clinical Orthopaedics & Related Research. 1991;(270):8–14
  8. Glasser DB, Lane JM, Huvos AG, Marcove RC, Rosen G. Survival, prognosis, and therapeutic response in osteogenic sarcoma: the memorial hospital experience. Cancer. 1992;69(3):698–708
  9. Grimer RJ. Surgical options for children with osteosarcoma. Lancet Oncology. 2005;6(2):85–92
  10. Akatsuka T, Wada T, Kokai Y, et al. ErbB2 expression is correlated with increased survival of patients with osteosarcoma. Cancer. 2002;94(5):1397–1404
  11. Baldini N, Scotlandi K, Barbanti-Brodano G, et al. Expression of p-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. New England Journal of Medicine. 1995;333(21):1380–1385
  12. Pakos EE, Ioannidis JP. The association of p-glycoprotein with response to chemotherapy and clinical outcome in patients with osteosarcoma. A meta-analysis. Cancer. 2003;98(3):581–589
  13. Pakos EE, Kyzas PA, Ioannidis JP. Prognostic significance of TP53 tumor suppressor gene expression and mutations in human osteosarcoma: a meta-analysis. Clinical Cancer Research. 2004;10(18 Pt 1):6208–6214
  14. Stein U, Shoemaker RH, Schlag PM. MDR1 gene expression: evaluation of its use as a molecular marker for prognosis and chemotherapy of bone and soft tissue sarcomas. European Journal of Cancer Part A: General Topics. 1996;32(1):86–92
  15. Trieb K, Kotz R. Proteins expressed in osteosarcoma and serum levels as prognostic factors. International Journal of Biochemistry & Cell Biology. 2001;33(1):11–17
  16. Saeter G, Elomaa I, Wahlqvist Y, et al. Prognostic factors in bone sarcomas. Acta Orthopaedica Scandinavica (Supplement). 1997;68(273):156–160
  17. Hayden JA, Cote P, Bombardier C. Evaluation of the quality of prognosis studies in systematic reviews. Annals of Internal Medicine. 2006;144(6):427–437
  18. Harbour R, Miller J. A new system for grading recommendations in evidence based guidelines. BMJ. 2001;323(7308):334–336
  19. Glasser DB, Lane JM. Stage IIB osteogenic sarcoma. Clinical Orthopaedics & Related Research. 1991;270:29–39
  20. Bieling P, Rehan N, Winkler P, et al. Tumor size and prognosis in aggressively treated osteosarcoma. Journal of Clinical Oncology. 1996;14(3):848–858
  21. Bacci G, Longhi A, Ferrari S, et al. Prognostic significance of serum lactate dehydrogenase in osteosarcoma of the extremity: experience at Rizzoli on 1421 patients treated over the last 30 years. Tumori. 2004;90(5):478–484
  22. Bacci G, Longhi A, Ferrari S, et al. Prognostic significance of serum alkaline phosphatase in osteosarcoma of the extremity treated with neoadjuvant chemotherapy: recent experience at Rizzoli Institute. Oncology Reports. 2002;9(1):171–175
  23. Bacci G, Ferrari S, Mercuri M, et al. Predictive factors for local recurrence in osteosarcoma: 540 patients with extremity tumors followed for minimum 2.5 years after neoadjuvant chemotherapy. Acta Orthopaedica Scandinavica. 1998;69(3):230–236
  24. Ferrari S, Bertoni F, Mercuri M, et al. Predictive factors of disease-free survival for non-metastatic osteosarcoma of the extremity: an analysis of 300 patients treated at the Rizzoli Institute. Annals of Oncology. 2001;12(8):1145–1150
  25. Smeland S, Muller C, Alvegard TA, et al. Scandinavian sarcoma group osteosarcoma study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders. European Journal of Cancer. 2003;39(4):488–494
  26. Enneking WF, Spinier SS, Goodman MA. Current concepts review. The surgical staging of musculoskeletal sarcoma. Journal of Bone and Joint Surgery (American). 1980;62(6):1027–1030
  27. Rehan N, Bieling P, Winkler P, et al. Assessing the best measure of tumor size as a prognostic factor in osteosarcoma after neoadjuvant chemotherapy. Klinische Padiatrie. 1993;205(4):200–209
  28. Bauer HCF. DNA cytometry of osteosarcoma. Acta Orthopaedica Scandinavica (Supplement). 1988;59(228):5–39
  29. Bentzen SM, Poulsen HS, Kaae S, et al. Prognostic factors in osteosarcomas. A regression analysis. Cancer. 1988;62(1):194–202
  30. Mantadakis E, Kim G, Reisch J, et al. Lack of prognostic significance of intratumoral angiogenesis in nonmetastatic osteosarcoma. Journal of Pediatric Hematology Oncology. 2001;23(5):286–289
  31. Szendroi M, Papai Z, Koos R, Illes T. Limb-saving surgery, survival, and prognostic factors for osteosarcoma: the Hungarian experience. Journal of Surgical Oncology. 2000;73(2):87–94
  32. Ger LP, Wang JW, Lin CC, Wang J. Prognostic factors in 43 cases of osteosarcoma. Journal of the Formosan Medical Association. 1993;92(11):962–968
  33. Kuryu M, Ozaki T, Nishida K, Shibahara M, Kawai A, Inoue H. Expression of CD44 variants in osteosarcoma. Journal of Cancer Research & Clinical Oncology. 1999;125(11):646–652
  34. Okada K, Hasegawa T, Yokoyama R, Beppu Y, Itoi E. Prognostic relevance of rosette-like features in osteosarcoma. Journal of Clinical Pathology. 2003;56(11):831–834
  35. Spanier SS, Shuster JJ, Vander Griend RA. The effect of local extent of the tumor on prognosis in osteosarcoma. Journal of Bone and Joint Surgery – Series A. 1990;72(5):643–653
  36. Stokkel MP, Linthorst MF, Borm JJ, Taminiau AH, Pauwels EK. A reassessment of bone scintigraphy and commonly tested pretreatment biochemical parameters in newly diagnosed osteosarcoma. Journal of Cancer Research and Clinical Oncology. 2002;128(7):393–399
  37. Tomer G, Cohen IJ, Kidron D, et al. Prognostic factors in non-metastatic limb osteosarcoma: a 20-year experience of one center. International Journal of Oncology. 1999;15(1):179–185
  38. Charity RM, Foukas AF, Deshmukh NS, Grimer RJ. Vascular endothelial growth factor expression in osteosarcoma. Clinical Orthopaedics & Related Research. 2006;448:193–198
  39. Reddick WE, Wang S, Xiong X, et al. Dynamic magnetic resonance imaging of regional contrast access as an additional prognostic factor in pediatric osteosarcoma. Cancer. 2001;91(12):2230–2237
  40. Uozaki H, Horiuchi H, Ishida T, Iijima T, Imamura T, Machinami R. Overexpression of resistance-related proteins (metallothioneins, glutathione-s-transferase Pi, heat shock protein 27, and lung resistance- related protein) in osteosarcoma: relationship with poor prognosis. Cancer. 1997;79(12):2336–2344
  41. Wunder JS, Bull SB, Aneliunas V, et al. MDR1 gene expression and outcome in osteosarcoma: a prospective, multicenter study. Journal of Clinical Oncology. 2000;18(14):2685–2694
  42. Baldini N, Scotlandi K, Serra M, et al. P-glycoprotein expression in osteosarcoma: a basis for risk-adapted adjuvant chemotherapy. Journal of Orthopaedic Research. 1999;17(5):629–632
  43. Chan HS, Grogan TM, Haddad G, DeBoer G, Ling V. P-glycoprotein expression: critical determinant in the response to osteosarcoma chemotherapy. Journal of National Cancer Institute. 1997;89(22):1706–1715
  44. Hornicek FJ, Gebhardt MC, Wolfe MW, et al. P-glycoprotein levels predict poor outcome in patients with osteosarcoma. Clinical Orthopaedics & Related Research. 2000;(373):11–17
  45. Serra M, Scotlandi K, Manara MC, et al. Analysis of p-glycoprotein expression in osteosarcoma. European Journal of Cancer. 1995;31A(12):1998–2002
  46. Yamamoto O, Wada T, Takahashi M, Yamawaki S, Ishii S. Prognostic value of p-glycoprotein expression in bone and soft-tissue sarcoma. International Journal of Clinical Oncology. 2000;5(3):164–170
  47. Park YB, Kim HS, Oh JH, Lee SH. The co-expression of P53 protein and p-glycoprotein is correlated to a poor prognosis in osteosarcoma. International Orthopaedics. 2001;24(6):307–310
  48. Morris CD, Gorlick R, Huvos AG, Heller G, Meyers PA, Healey JH. Human epidermal growth factor receptor 2 as a prognostic indicator in osteogenic sarcoma. Clinical Orthopaedics & Related Research. 2001;(382):59–65
  49. Onda M, Matsuda S, Higaki S, et al. ErbB-2 expression is correlated with poor prognosis for patients with osteosarcoma. Cancer. 1996;77(1):71–78
  50. Scotlandi K, Manara MC, Hattinger CM, et al. Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing's sarcoma. European Journal of Cancer. 2005;41(9):1349–1361
  51. Gorlick R, Huvos AG, Heller G, et al. Expression of HER2/ErbB-2 correlates with survival in osteosarcoma. Journal of Clinical Oncology. 1999;17(9):2781–2788
  52. Kaya M, Wada T, Kawaguchi S, et al. Increased pre-therapeutic serum vascular endothelial growth factor in patients with early clinical relapse of osteosarcoma. British Journal of Cancer. 2002;86(6):864–869
  53. Kaya M, Wada T, Akatsuka T, et al. Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. Clinical Cancer Research. 2000;6(2):572–577
  54. Lee YH, Tokunaga T, Oshika Y, et al. Cell-retained isoforms of vascular endothelial growth factor (VEGF) are correlated with poor prognosis in osteosarcoma. European Journal of Cancer. 1999;35(7):1089–1093
  55. Feugeas O, Guriec N, Babin-Boilletot A, et al. Loss of heterozygosity of the RB gene is a poor prognostic factor in patients with osteosarcoma. Journal of Clinical Oncology. 1996;14(2):467–472
  56. Bentzen SM. Prognostic factor studies in oncology: osteosarcoma as a clinical example. International Journal of Radiation Oncology, Biology, Physics. 2001;49(2):513–518
  57. Dorfman HD, Czerniak B. Bone cancers. Cancer. 1995;75(1 Suppl.):203–210

PII: S0748-7983(09)00028-6

doi: 10.1016/j.ejso.2009.01.011

European Journal of Surgical Oncology
Volume 35, Issue 10 , Pages 1030-1036 , October 2009

Article Tools

* Image Usage & Resolution